MARIA E CABANILLAS

TitleAssociate Professor
InstitutionMD Anderson
DepartmentEndocrine Neoplasia & HD
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Nies M, Vassilopoulou-Sellin R, Bassett RL, Yedururi S, Zafereo ME, Cabanillas ME, Sherman SI, Links TP, Waguespack SG. Distant metastases from childhood differentiated thyroid carcinoma: clinical course and mutational landscape. J Clin Endocrinol Metab. 2020 Dec 31. PMID: 33382403.
      Citations:    Fields:    
    2. Datar S, Cabanillas M, Dadu R, Ost D, Grosu HB. Pulmonary cavitation in patients with thyroid cancer receiving antiangiogenic agents. BMC Cancer. 2020 Dec 02; 20(1):1181. PMID: 33267782.
      Citations: 1     Fields:    
    3. Srivastava A, Nogueras Gonzalez GM, Geng Y, Won AM, Cabanillas ME, Naing A, Myers JN, Li Y, Chambers MS. Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer. 2020 Nov 15. PMID: 33190182.
      Citations:    Fields:    
    4. Jozaghi Y, Zafereo M, Williams MD, Gule-Monroe MK, Wang J, Grubbs EG, Vaporciyan A, Hu MI, Busaidy N, Dadu R, Waguespack SG, Subbiah V, Cabanillas M. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck. 2021 Jan; 43(1):E7-E12. PMID: 33169506.
      Citations: 1     Fields:    
    5. Andreev-Drakhlin A, Cabanillas M, Amini B, Subbiah V. Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases. JCO Precis Oncol. 2020; 4. PMID: 33154983.
      Citations:    
    6. Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open. 2020 10; 5(5):e000799. PMID: 33097651.
      Citations:    
    7. Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, Williams MD, Gunn GB, Hofmann MC, Cote G, Sperling J, Gross ND, Sturgis EM, Goepfert RP, Lai SY, Cabanillas ME, Zafereo M. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol. 2020 09 01; 6(9):1397-1404. PMID: 32761153.
      Citations:    Fields:    Translation:Humans
    8. Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 08 27; 383(9):825-835. PMID: 32846061.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    9. Cabanillas ME, Dadu R, Iyer P, Wanland KB, Busaidy NL, Ying A, Gule-Monroe M, Wang JR, Zafereo M, Hofmann MC. Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid. 2020 09; 30(9):1288-1296. PMID: 32216548.
      Citations: 2     Fields:    
    10. Jozaghi Y, Zafereo ME, Perrier ND, Wang JR, Grubbs E, Gross ND, Fisher S, Sturgis EM, Goepfert RP, Lai SY, Best C, Busaidy NL, Cabanillas ME, Dadu R, Gagel RF, Habra MA, Hu MI, Jimenez C, Sherman SI, Thosani S, Varghese J, Waguespack SG, Weitzman S, Ying AK, Graham PH. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck. 2020 06; 42(6):1325-1328. PMID: 32437031.
      Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
    11. Boyce-Fappiano D, Gjyshi O, Pezzi TA, Allen PK, Solimman M, Taku N, Bernstein MB, Cabanillas ME, Amini B, Tatsui CE, Rhines LD, Wang XA, Briere TM, Yeboa DN, Bishop AJ, Li J, Ghia AJ. Spine stereotactic radiosurgery for metastatic thyroid cancer: a single-institution experience. J Neurosurg Spine. 2020 Feb 14; 1-9. PMID: 32059183.
      Citations: 1     Fields:    
    12. Cabanillas ME, Ryder M, Jimenez C. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. Endocr Rev. 2019 12 01; 40(6):1573-1604. PMID: 31322645.
      Citations: 13     Fields:    Translation:HumansAnimals
    13. Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909. PMID: 31658994.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    14. Maxwell JE, Gule-Monroe MK, Subbiah V, Hu M, Perrier ND, Cabanillas ME, Lee JE, Graham PH, Cote GJ, Busaidy NL, Grubbs EG. Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma. Surgery. 2020 01; 167(1):80-86. PMID: 31648931.
      Citations: 2     Fields:    Translation:Humans
    15. Angell TE, Wirth LJ, Cabanillas ME, Shindo ML, Cibas ES, Babiarz JE, Hao Y, Kim SY, Walsh PS, Huang J, Kloos RT, Kennedy GC, Waguespack SG. Analytical and Clinical Validation of Expressed Variants and Fusions From the Whole Transcriptome of Thyroid FNA Samples. Front Endocrinol (Lausanne). 2019; 10:612. PMID: 31572297.
      Citations:    
    16. Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019 08; 29(8):1036-1043. PMID: 31319771.
      Citations: 9     Fields:    Translation:Humans
    17. Tetzlaff MT, Tang S, Duke T, Grabell DA, Cabanillas ME, Zuo Z, Yao JC, Nagarajan P, Aung PP, Torres-Cabala CA, Duvic M, Prieto VG, Huen A, Curry JL. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features. J Cutan Pathol. 2019 Nov; 46(11):872-877. PMID: 31254410.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    18. Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol. 2019 Aug; 145(8):1977-1986. PMID: 31309300.
      Citations: 1     Fields:    Translation:Humans
    19. Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head Neck. 2019 06; 41(6):1928-1934. PMID: 30758123.
      Citations: 4     Fields:    Translation:Humans
    20. Ye W, Hannigan B, Zalles S, Mehrotra M, Barkoh BA, Williams MD, Cabanillas ME, Edeiken-Monroe B, Hu P, Duose D, Wistuba II, Medeiros LJ, Stewart J, Luthra R, Roy-Chowdhuri S. Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules. Cancer Cytopathol. 2019 03; 127(3):146-160. PMID: 30620446.
      Citations: 3     Fields:    Translation:Humans
    21. Kazzaz FI, Cabanillas ME, Bashoura L, Shannon VR, Faiz SA. Bilateral spontaneous pneumothoraces in anaplastic thyroid cancer. Respir Med Case Rep. 2019; 26:197-199. PMID: 30705818.
      Citations:    
    22. Sagiv O, Kandl TJ, Thakar SD, Thuro BA, Busaidy NL, Cabanillas M, Jimenez C, Dadu R, Graham PH, Debnam JM, Esmaeli B. Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients. Ophthalmic Plast Reconstr Surg. 2019 Jan/Feb; 35(1):50-52. PMID: 29927883.
      Citations: 3     Fields:    Translation:Humans
    23. Cabanillas ME, Takahashi S. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin Oncol. 2019 02; 46(1):57-64. PMID: 30685073.
      Citations: 1     Fields:    Translation:Humans
    24. Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, Busaidy NL, Subudhi SK, Diab A, Dadu R. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid. 2018 10; 28(10):1243-1251. PMID: 30132401.
      Citations: 10     Fields:    Translation:Humans
    25. Tam S, Boonsripitayanon M, Amit M, Fellman BM, Li Y, Busaidy NL, Cabanillas ME, Dadu R, Sherman S, Waguespack SG, Williams MD, Goepfert RP, Gross ND, Perrier ND, Sturgis EM, Zafereo ME. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions. Thyroid. 2018 10; 28(10):1301-1310. PMID: 30141373.
      Citations: 15     Fields:    Translation:Humans
    26. Jaber T, Waguespack SG, Cabanillas ME, Elbanan M, Vu T, Dadu R, Sherman SI, Amit M, Santos EB, Zafereo M, Busaidy NL. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine. J Clin Endocrinol Metab. 2018 10 01; 103(10):3698-3705. PMID: 30032208.
      Citations: 7     Fields:    Translation:Humans
    27. Puli OR, Danysh BP, McBeath E, Sinha DK, Hoang NM, Powell RT, Danysh HE, Cabanillas ME, Cote GJ, Hofmann MC. The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells. Neoplasia. 2018 11; 20(11):1121-1134. PMID: 30265861.
      Citations: 3     Fields:    Translation:HumansCells
    28. Rao SN, Cabanillas ME. Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond. J Endocr Soc. 2018 Oct 01; 2(10):1109-1130. PMID: 30250937.
      Citations:    
    29. Tam S, Amit M, Boonsripitayanon M, Busaidy NL, Cabanillas ME, Waguespack SG, Gross ND, Grubbs EG, Williams MD, Lai SY, Sturgis EM, Zafereo ME. Effect of Tumor Size and Minimal Extrathyroidal Extension in Patients with Differentiated Thyroid Cancer. Thyroid. 2018 08; 28(8):982-990. PMID: 29936892.
      Citations: 7     Fields:    Translation:Humans
    30. Amit M, Boonsripitayanon M, Goepfert RP, Tam S, Busaidy NL, Cabanillas ME, Dadu R, Varghese J, Waguespack SG, Gross ND, Graham P, Williams MD, Sturgis EM, Zafereo ME. Extrathyroidal Extension: Does Strap Muscle Invasion Alone Influence Recurrence and Survival in Patients with Differentiated Thyroid Cancer? Ann Surg Oncol. 2018 Oct; 25(11):3380-3388. PMID: 30022274.
      Citations: 4     Fields:    Translation:Humans
    31. Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018 07 11; 6(1):68. PMID: 29996921.
      Citations: 27     Fields:    Translation:Humans
    32. Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, Williams MD, Skinner H, Gunn GB, Grosu H, Iyer P, Hofmann MC, Zafereo M. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid. 2018 07; 28(7):945-951. PMID: 29742974.
      Citations: 19     Fields:    Translation:Humans
    33. Chen H, Luthra R, Routbort MJ, Patel KP, Cabanillas ME, Broaddus RR, Williams MD. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy. . 2018 07; 17(7):1575-1584. PMID: 29695638.
      Citations:    
    34. Smith AL, Williams MD, Stewart J, Wang WL, Krishnamurthy S, Cabanillas ME, Roy-Chowdhuri S. Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma. Cancer Cytopathol. 2018 06; 126(6):406-413. PMID: 29579361.
      Citations: 3     Fields:    Translation:Humans
    35. Amit M, Tam S, Boonsripitayanon M, Cabanillas ME, Busaidy NL, Grubbs EG, Lai SY, Gross ND, Sturgis EM, Zafereo ME. Association of Lymph Node Density With Survival of Patients With Papillary Thyroid Cancer. JAMA Otolaryngol Head Neck Surg. 2018 02 01; 144(2):108-114. PMID: 29192312.
      Citations: 6     Fields:    Translation:Humans
    36. Cabanillas ME, Zafereo M, Williams MD, Ferrarotto R, Dadu R, Gross N, Gunn GB, Skinner H, Cote G, Grosu HB, Iyer P, Busaidy NL. Recent advances and emerging therapies in anaplastic thyroid carcinoma. F1000Res. 2018; 7. PMID: 31583077.
      Citations: 4     Fields:    
    37. Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res. 2018 04 01; 24(7):1546-1553. PMID: 29301825.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    38. Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid. 2018 01; 28(1):79-87. PMID: 29161986.
      Citations: 17     Fields:    Translation:Humans
    39. Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F. Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. . 2018 03; 17(3):671-676. PMID: 29237802.
      Citations:    
    40. Tam S, Amit M, Boonsripitayanon M, Cabanillas ME, Busaidy NL, Gunn GB, Lai SY, Gross ND, Sturgis EM, Zafereo ME. Adjuvant External Beam Radiotherapy in Locally Advanced Differentiated Thyroid Cancer. JAMA Otolaryngol Head Neck Surg. 2017 12 01; 143(12):1244-1251. PMID: 29098272.
      Citations: 3     Fields:    Translation:Humans
    41. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2018 01 01; 36(1):7-13. PMID: 29072975.
      Citations: 104     Fields:    Translation:HumansCTClinical Trials
    42. Pena I, Clayman GL, Grubbs EG, Bergeron JM, Waguespack SG, Cabanillas ME, Dadu R, Hu MI, Fellman BM, Li Y, Gross ND, Lai SY, Sturgis EM, Zafereo ME. Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer. Head Neck. 2018 Jan; 40(1):79-85. PMID: 29044788.
      Citations: 2     Fields:    Translation:Humans
    43. Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2017 09 01; 102(9):3591-3599. PMID: 28911154.
      Citations: 6     Fields:    Translation:Humans
    44. Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, Shah K, Wright J, Shah MH. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. J Clin Oncol. 2017 Oct 10; 35(29):3315-3321. PMID: 28817373.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    45. Voss RK, Feng L, Lee JE, Perrier ND, Graham PH, Hyde SM, Nieves-Munoz F, Cabanillas ME, Waguespack SG, Cote GJ, Gagel RF, Grubbs EG. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. J Clin Endocrinol Metab. 2017 08 01; 102(8):2807-2813. PMID: 28609830.
      Citations: 8     Fields:    Translation:Humans
    46. Cabanillas ME, Terris DJ, Sabra MM. Information for Clinicians: Approach to the Patient with Progressive Radioiodine-Refractory Thyroid Cancer-When to Use Systemic Therapy. Thyroid. 2017 Aug; 27(8):987-993. PMID: 28635520.
      Citations: 3     Fields:    
    47. Cabanillas ME, Williams MD, Gunn GB, Weitzman SP, Burke L, Busaidy NL, Ying AK, Yiin YH, William WN, Lu C, Lai SY. Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer. Head Neck. 2017 07; 39(7):1291-1295. PMID: 28452157.
      Citations: 1     Fields:    Translation:Humans
    48. Rao SN, Zafereo M, Dadu R, Busaidy NL, Hess K, Cote GJ, Williams MD, William WN, Sandulache V, Gross N, Gunn GB, Lu C, Ferrarotto R, Lai SY, Cabanillas ME. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid. 2017 05; 27(5):672-681. PMID: 28068873.
      Citations: 20     Fields:    Translation:Humans
    49. Pezzi TA, Mohamed ASR, Sheu T, Blanchard P, Sandulache VC, Lai SY, Cabanillas ME, Williams MD, Pezzi CM, Lu C, Garden AS, Morrison WH, Rosenthal DI, Fuller CD, Gunn GB. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. Cancer. 2017 05 01; 123(9):1653-1661. PMID: 28026871.
      Citations: 13     Fields:    Translation:Humans
    50. Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, Cote GJ, Singh RR, Luthra R, Cabanillas ME. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid. 2017 01; 27(1):81-87. PMID: 27785980.
      Citations: 15     Fields:    Translation:Humans
    51. Grubbs EG, Williams MD, Scheet P, Vattathil S, Perrier ND, Lee JE, Gagel RF, Hai T, Feng L, Cabanillas ME, Cote GJ. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma. Thyroid. 2016 11; 26(11):1553-1562. PMID: 27610696.
      Citations: 7     Fields:    Translation:Humans
    52. Xu JY, Murphy WA, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4871-4877. PMID: 27662441.
      Citations: 6     Fields:    Translation:Humans
    53. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396. PMID: 27649551.
      Citations: 83     Fields:    Translation:HumansCellsCTClinical Trials
    54. Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA, Cote GJ, Sherman SI. Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4461-4467. PMID: 27575943.
      Citations: 6     Fields:    Translation:HumansCells
    55. Bernstein MB, Chang EL, Amini B, Pan H, Cabanillas M, Wang XA, Allen PK, Rhines LD, Tatsui C, Li J, Brown PD, Ghia AJ. Spine Stereotactic Radiosurgery for Patients with Metastatic Thyroid Cancer: Secondary Analysis of Phase I/II Trials. Thyroid. 2016 09; 26(9):1269-75. PMID: 27334245.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    56. Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1272-82. PMID: 27460442.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    57. Cabanillas ME, Zafereo M, Gunn GB, Ferrarotto R. Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy. J Oncol Pract. 2016 06; 12(6):511-8. PMID: 27288464.
      Citations: 26     Fields:    Translation:Humans
    58. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016 12 03; 388(10061):2783-2795. PMID: 27240885.
      Citations: 132     Fields:    Translation:Humans
    59. Danysh BP, Rieger EY, Sinha DK, Evers CV, Cote GJ, Cabanillas ME, Hofmann MC. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Oncotarget. 2016 May 24; 7(21):30907-23. PMID: 27127178.
      Citations: 19     Fields:    Translation:HumansCells
    60. Cabanillas ME, Williams MD. Letter to the Editor regarding squamoid pattern of anaplastic thyroid carcinoma, a poorly recognized entity. Head Neck. 2016 08; 38(8):1290. PMID: 27198734.
      Citations:    Fields:    Translation:Humans
    61. Pezzi TA, Sandulache VC, Pezzi CM, Turkeltaub AE, Feng L, Cabanillas ME, Williams MD, Lai SY. Treatment and survival of patients with insular thyroid carcinoma: 508 cases from the National Cancer Data Base. Head Neck. 2016 06; 38(6):906-12. PMID: 26843481.
      Citations: 5     Fields:    Translation:Humans
    62. Cabanillas ME, Habra MA. Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev. 2016 Jan; 42:47-55. PMID: 26678514.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    63. Cabanillas ME, Dadu R, Hu MI, Lu C, Gunn GB, Grubbs EG, Lai SY, Williams MD. Thyroid Gland Malignancies. Hematol Oncol Clin North Am. 2015 Dec; 29(6):1123-43. PMID: 26568552.
      Citations: 5     Fields:    Translation:Humans
    64. Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):44-53. PMID: 26311725.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    65. Dadu R, Hu MI, Cleeland C, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying A, Fox P, Cabanillas ME. Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid. 2015 Oct; 25(10):1085-90. PMID: 26200040.
      Citations: 6     Fields:    Translation:Humans
    66. Weitzman SP, Cabanillas ME. The treatment landscape in thyroid cancer: a focus on cabozantinib. Cancer Manag Res. 2015; 7:265-78. PMID: 26316818.
      Citations:    
    67. Ozsari L, Kutahyalioglu M, Elsayes KM, Vicens RA, Sircar K, Jazaerly T, Waguespack SG, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Vassilopoulou-Sellin R, Jimenez C, Lee JE, Habra MA. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine. 2016 Feb; 51(2):351-9. PMID: 26206754.
      Citations: 6     Fields:    Translation:Humans
    68. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. 2015 Aug 15; 121(16):2749-56. PMID: 25913680.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    69. Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab. 2015 Jan; 100(1):E77-81. PMID: 25353071.
      Citations: 35     Fields:    Translation:Humans
    70. Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2015 Jan; 25(1):71-7. PMID: 25285888.
      Citations: 35     Fields:    Translation:Humans
    71. Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S, Falchook G. BRAF inhibitors: experience in thyroid cancer and general review of toxicity. Horm Cancer. 2015 Feb; 6(1):21-36. PMID: 25467940.
      Citations: 19     Fields:    Translation:Humans
    72. Cabanillas ME, Hu MI, Jimenez C. Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions. J Clin Endocrinol Metab. 2014 Dec; 99(12):4390-6. PMID: 25238206.
      Citations: 12     Fields:    Translation:Humans
    73. Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid. 2014 Oct; 24(10):1508-14. PMID: 25102375.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    74. Cabanillas ME, Dadu R, Lai SY. In reply. Oncologist. 2014 Aug; 19(8):e4. PMID: 25052450.
      Citations:    Fields:    Translation:Humans
    75. Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, Arfi-Roufe J, Berdelou A, Moon B, Al Ghuzlan A, Patel S, Leboulleux S, Jimenez C. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol. 2014 Sep; 171(3):R111-22. PMID: 24891137.
      Citations: 33     Fields:    Translation:HumansAnimals
    76. Holsinger FC, Ramaswamy U, Cabanillas ME, Lang J, Lin HY, Busaidy NL, Grubbs E, Rahim S, Sturgis EM, Lee JE, Weber RS, Clayman GL, Rohren EM. Measuring the extent of total thyroidectomy for differentiated thyroid carcinoma using radioactive iodine imaging: relationship with serum thyroglobulin and clinical outcomes. JAMA Otolaryngol Head Neck Surg. 2014 May; 140(5):410-5. PMID: 24700275.
      Citations: 3     Fields:    Translation:Humans
    77. Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014 May; 19(5):477-82. PMID: 24733667.
      Citations: 9     Fields:    Translation:Humans
    78. Blevins DP, Dadu R, Hu M, Baik C, Balachandran D, Ross W, Gunn B, Cabanillas ME. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid. 2014 May; 24(5):918-22. PMID: 24635127.
      Citations: 22     Fields:    Translation:Humans
    79. Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014 Jun; 99(6):2086-94. PMID: 24628550.
      Citations: 24     Fields:    Translation:Humans
    80. Thomas L, Lai SY, Dong W, Feng L, Dadu R, Regone RM, Cabanillas ME. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist. 2014 Mar; 19(3):251-8. PMID: 24563075.
      Citations: 31     Fields:    Translation:Humans
    81. Cabanillas ME, Hu MI, Jimenez C, Grubbs EG, Cote GJ. Treating medullary thyroid cancer in the age of targeted therapy. Int J Endocr Oncol. 2014; 1(2):203-216. PMID: 25908961.
      Citations:    
    82. Ganeshan D, Paulson E, Duran C, Cabanillas ME, Busaidy NL, Charnsangavej C. Current update on medullary thyroid carcinoma. AJR Am J Roentgenol. 2013 Dec; 201(6):W867-76. PMID: 24261394.
      Citations: 10     Fields:    Translation:Humans
    83. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid. 2013 Oct; 23(10):1277-83. PMID: 23489023.
      Citations: 70     Fields:    Translation:HumansCTClinical Trials
    84. Hightower E, Cabanillas ME, Fuller GN, McCutcheon IE, Hess KR, Shah K, Waguespack SG, Corley LJ, Devin JK. Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas. Pituitary. 2012 Dec; 15(4):556-61. PMID: 22120760.
      Citations: 3     Fields:    Translation:HumansCells
    85. Dadu R, Cabanillas ME. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions. Minerva Endocrinol. 2012 Dec; 37(4):335-56. PMID: 23235190.
      Citations: 14     Fields:    Translation:Humans
    86. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013 Jan; 98(1):31-42. PMID: 23185034.
      Citations: 25     Fields:    Translation:Humans
    87. Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, Caramella C, Anderson P, Al Ghuzlan A, Waguespack SG, Deandreis D, Baudin E, Jimenez C. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. 2012 Nov; 97(11):4040-50. PMID: 22965939.
      Citations: 50     Fields:    Translation:Humans
    88. Del Fabbro E, Dev R, Cabanillas ME, Busaidy NL, Rodriguez EC, Bruera E. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer. J Chemother. 2012 Aug; 24(4):221-5. PMID: 23040687.
      Citations: 4     Fields:    Translation:Humans
    89. Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, Yeung SC. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):355-62. PMID: 22658895.
      Citations: 12     Fields:    Translation:Humans
    90. Cabanillas ME, Sherman SI. Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma. Endocr Relat Cancer. 2012 Apr; 19(2):C19-22. PMID: 22241721.
      Citations: 1     Fields:    Translation:Humans
    91. Busaidy NL, Cabanillas ME. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res. 2012; 2012:618985. PMID: 22530159.
      Citations:    
    92. M Bugalho MJ, Wohllk N, Hoff AO, Cabanillas ME. Thyroid oncology. J Thyroid Res. 2011; 2011:467570. PMID: 22007337.
      Citations:    
    93. Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res. 2011; 2011:985780. PMID: 22007339.
      Citations:    
    94. Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. Cancer. 2012 Feb 01; 118(3):848-55. PMID: 21751205.
      Citations: 4     Fields:    Translation:Humans
    95. Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, Ying AK, Cabanillas M, Abbara M, Habra MA. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. Cancer. 2011 Oct 01; 117(19):4381-9. PMID: 21412758.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    96. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005. PMID: 21289252.
      Citations: 32     Fields:    Translation:HumansCellsCTClinical Trials
    97. Mattiuzzi GN, Cortes JE, Blamble DA, Bekele BN, Xiao L, Cabanillas M, Borthakur G, O'Brien S, Kantarjian H. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer. 2010 Dec 15; 116(24):5659-66. PMID: 21218459.
      Citations: 12     Fields:    Translation:Humans
    98. Garcia-Doval I, Cabo F, Monteagudo B, Alvarez J, Ginarte M, Rodríguez-Alvarez MX, Abalde MT, Fernández ML, Allegue F, Pérez-Pérez L, Flórez A, Cabanillas M, Peón G, Zulaica A, Del Pozo J, Gomez-Centeno P. Clinical diagnosis of toenail onychomycosis is possible in some patients: cross-sectional diagnostic study and development of a diagnostic rule. Br J Dermatol. 2010 Oct; 163(4):743-51. PMID: 20618320.
      Citations: 4     Fields:    Translation:HumansAnimals
    99. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010 Jun; 95(6):2588-95. PMID: 20392874.
      Citations: 70     Fields:    Translation:Humans
    100. Hernández A, Domper F, León A, Lorente R, López B, de la Santa E, Cabanillas M, Patón R, Olmedo J, Galván MD, Rodríguez E. Viral kinetics during the first month of treatment in patients with genotype 1 chronic hepatitis C. Rev Esp Enferm Dig. 2009 Oct; 101(10):671-9. PMID: 19899935.
      Citations: 1     Fields:    Translation:HumansCells
    101. Monteagudo Sánchez B, Cabanillas M, Caínzos T, Used-Aznar MM. [Merkel cell carcinoma of the breast]. Actas Dermosifiliogr. 2009 Mar; 100(2):151-2. PMID: 19445883.
      Citations:    Fields:    Translation:Humans
    102. Ginarte M, Garcia-Doval I, Monteagudo B, Cabanillas M, Labandeira J, Florez A, Cabo F, Alvarez J, Zulaica A, Allegue F, Pérez L, Abalde MT, Rosón E, de la Torre C, Rodríguez MX. Observer agreement in toenail disorders: implications for diagnosis and clinical research. Br J Dermatol. 2009 Jun; 160(6):1315-7. PMID: 19239464.
      Citations:    Fields:    Translation:Humans
    103. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab. 2009 Feb; 94(2):386-91. PMID: 19017755.
      Citations: 39     Fields:    Translation:Humans
    104. León-Muiños E, Monteagudo B, Labandeira J, Cabanillas M. [Bilateral congenital triangular alopecia associated with congenital heart disease and renal and genital abnormalities]. Actas Dermosifiliogr. 2008 Sep; 99(7):578-9. PMID: 18682178.
      Citations: 2     Fields:    Translation:Humans
    105. Cabanillas M, Rodríguez-Blanco I, Sánchez-Aguilar D, Toribio J. [Sweet syndrome as a possible initial manifestation of human immunodeficiency virus infection]. Actas Dermosifiliogr. 2008 Jan-Feb; 99(1):83-4. PMID: 18206098.
      Citations: 1     Fields:    Translation:Humans
    106. Cabanillas ME, Lu H, Fang S, Du XL. Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures. Leuk Lymphoma. 2007 Aug; 48(8):1514-21. PMID: 17701582.
      Citations: 6     Fields:    Translation:Humans
    107. Torres HA, Aguilera EA, Mattiuzzi GN, Cabanillas ME, Rohatgi N, Sepulveda CA, Kantarjian HM, Jiang Y, Safdar A, Raad II, Chemaly RF. Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. Haematologica. 2007 Sep; 92(9):1216-23. PMID: 17666367.
      Citations: 14     Fields:    Translation:HumansCells
    108. Berrios-Rivera JP, Fang S, Cabanillas ME, Cabanillas F, Lu H, Du XL. Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma. Am J Clin Oncol. 2007 Apr; 30(2):163-71. PMID: 17414466.
      Citations: 7     Fields:    Translation:Humans
    109. Chemaly RF, Torres HA, Aguilera EA, Mattiuzzi G, Cabanillas M, Kantarjian H, Gonzalez V, Safdar A, Raad II. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis. 2007 Apr 01; 44(7):964-7. PMID: 17342649.
      Citations: 10     Fields:    Translation:Humans
    110. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007 Apr 15; 109(8):3214-8. PMID: 17209054.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    111. Weiser MA, Cabanillas M, Vu K, Tamm EP, Wallace MJ, Escalante CP, Bresalier RS. Diagnostic evaluation of patients with a high suspicion of malignancy: comorbidities and clinical predictors of cancer. Am J Med Sci. 2005 Jul; 330(1):11-8. PMID: 16020994.
      Citations: 1     Fields:    Translation:Humans
    112. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004 Mar 15; 100(6):1179-85. PMID: 15022284.
      Citations: 59     Fields:    Translation:Humans
    113. Spine Stereotactic Radiosurgery for Patients with Metastatic Thyroid Cancer. Thyroid. 26:1269-1275.
    114. Treatment and survival of patients with insular thyroid carcinoma. Head and Neck.
    115. Anaplastic thyroid carcinoma. Journal of Oncology Practice. 12:511-518.
    116. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma. Cancer.
    117. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clinical Cancer Research. 22:44-53.
    118. Targets by organ site.
    119. Role of CDKN2C copy number in sporadic medullary thyroid carcinoma. Thyroid. 26:1553-1562.
    120. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid. 27:81-87.
    121. Re. Oncologist. 19.
    122. Bone metastases and skeletal-related events in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 101:4871-4877.
    123. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005). Journal of Clinical Endocrinology and Metabolism. 96:2286.
    124. Efficacy of the natural clay, calcium aluminosilicate anti-diarrheal, in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life. Thyroid. 25:1085-1090.
    125. Efficacy and tolerability of vemurafenib in patients with BRAFV600E positive papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 100:E77-E81.
    126. The treatment landscape in thyroid cancer. Cancer Management and Research. 7:265-278.
    127. Thyroid cancer. The Lancet.
    128. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine. The Lancet Oncology. 17:1272-1282.
    129. Detection and prognostic significance of circulating tumor cells in patients with metastatic thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 101:4461-4467.
    130. Preexisting adrenal masses in patients with adrenocortical carcinoma. Endocrine.
    131. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, (997-1005)). Journal of Clinical Endocrinology and Metabolism. 97:1399.
    132. Long-Term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Oncotarget. 7:30907-30923.
    CABANILLAS's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (407)
    Explore
    _
    Co-Authors (150)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _